�������

News from ������� Langone Health

������� Langone Health Beekeeping Program Promotes Biodiversity And Healing. (WNYW-NY (FOX)-3)

(6/3) �����о��� Langone Health’s urban beekeeping program, featuring 23,000 square feet of green roofs, promotes biodiversity and healing by allowing bees to pollinate native flowers and nearby parks, according to Jocelyn Gan, energy and sustainability specialist, who said, “We love green spaces because they help so much with healing”; Kristen Rydberg, Alvéole’s beekeeping manager, demonstrated holding a honey bee frame to foster a connection with nature, while Alvéole Urban Beekeeper Will Duncan explained the use of a smoker to mask danger pheromones, noting that the bees are “relatively docile” and likening their temperament to dairy cows.

Also reporting is (6/3). 

Elderly Embrace Cannabis: 46% Increase In Senior Weed Use. (HealthDay)

(6/3) A study published June 2 in JAMA Internal Medicine found that marijuana use among seniors 65 and older in the U.S. increased to 7% in 2023, a 46% increase from 2021, with Joseph J. Palamar, MPH, PhD, associate professor, Department of Population Health, saying, “It shouldn’t be surprising that use is becoming increasingly more common among people who live in states that allow medical cannabis, which could be due to increased availability or social acceptability.”

Record High: Study Finds Growing Cannabis Use Among Older Adults.

(6/2) Joseph J. Palamar, MPH, PhD, associate professor, Department of Population Health said, “Our study shows that cannabis use among older adults continues to increase, although there have been major shifts in use according to demographic and socioeconomic factors.”

Also reporting are (6/3), (6/3), (6/3), and (6/3).

14 Physician CEOs To Know In 2025. (Becker's Physician Leadership)

(6/3) A roundup shares that ������� Langone Health has selected Alec Kimmelman, MD, PhD, the Anita Steckler and Joseph Steckler Chair, and professor, Department of Radiation Oncology, Perlmutter Cancer Center, as the next CEO of ������� Langone Health and dean of ������� Grossman School of Medicine, as of Sept. 1.

Food & Gut Microbiota Immune Tolerance Driven By Newly Identified Rare Cells. (Physician's Weekly)

(6/3) A study published in Nature by Liuhui Fu, PhD, postdoctoral fellow, Department of Cell Biology, and colleagues, identified a rare dendritic cell population, characterized by the co-expression of transcription factors Prdm16 and RORγt, crucial for promoting tolerance to dietary and microbiota-derived antigens in the gut, with disruptions in these cells leading to inflammation and allergic sensitization in mouse models; the research also highlights the potential therapeutic relevance of these cells, termed tolerogenic dendritic cells, for conditions like food allergies and asthma, and their evolutionary conservation across species, suggesting a viable target for modulating immune tolerance.

Clinical Validation Data For Freenome Blood-Based CRC Test Shows “Acceptable” Screening Accuracy. (GenomeWeb)

(6/3) A study published in JAMA found Freenome’s blood test detected colorectal cancer with 79.2% sensitivity and 91.5% specificity for advanced colorectal neoplasias, although sensitivity for advanced precancerous lesions was lower than expected, with first author Aasma Shaukat, MD, MPH, the Robert M. and Mary H. Glickman Professor of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, professor, Department of Population Health, saying, “This test has the potential to increase screening uptake, especially among people who might otherwise delay or avoid screening.”

Youth Deaths Attributable To Synthetic Opioids Alone Increasingly Predominant. (Clinical Pain Advisor)

(6/3) A study led by Megan Miller, MPH, research coordinator, Center for Opioid Epidemiology and Policy, found that overdose deaths among U.S. youth aged 15 to 24 involving synthetic opioids alone saw the largest increases from 2018 to 2022, with the authors writing, “These findings shed light on the changing realities and risks of the drug supply and how they impact key demographic groups and the urgent need for education and harm-reduction efforts tailored to youth to prevent further death and suffering among this important and understudied population.”

ASCO 2025: Zongertinib Shows Strong Potential In HER2-Mutant NSCLC Treatment Landscape. (Pharmacy Times)

(6/3) Data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on Boehringer Ingelheim’s zongertinib, showed a 71% objective response rate and a favorable safety profile in patients with HER2-mutant advanced non-small cell lung cancer (NSCLC) in the Beamion LUNG-1 study, with presenter Joshua K. Sabari, MD, assistant professor, Department of Medicine, Division of Hematology and Medical Oncology, Perlmutter Cancer Center, saying, “Educating pharmacists on the mechanism of action is critical,” noting it is “an HER2-selective TKI” and it “spares epidermal growth factor receptor (EGFR).”

1st Patients Treated In Moximed’s New MISHA Knee System Trial. (Orthopedic Design & Technology Magazine)

(6/3) Moximed has commenced a new randomized controlled trial to assess the MISHA knee system, an implantable shock absorber for medial knee osteoarthritis, compared to non-surgical treatments, with ������� Langone Health among the ten U.S. sites enrolling up to 100 patients.

Billion-Dollar Breakthroughs: Inside The Global Race To Extend Human Healthspan. (Forbes)

(6/3) At the Hevolution Global Healthspan Summit 2025, discussions centered on the potential for healthspan technologies to reach a global market of eight billion people, with Dr. Mehmood Khan, CEO of Hevolution, comparing the endeavor to a “moonshot” requiring global collaboration; Dr. Anshu Banerjee of the WHO highlighted the growing gap between life expectancy and healthspan, especially for women, while regulatory innovations in Saudi Arabia and the ethical imperatives outlined by Art Caplan, PhD, the Drs. William F. and Virginia Connolly Mitty Professor of Bioethics, Department of Population Health, Division of Medical Ethics, emphasized the need for equitable access to healthspan advancements, which could reduce healthcare costs and support workforce participation, particularly for women.

The 3 Times You Should NOT Drink Lemon Water. (Texas Metro News)

(6/3) Lemon water, often praised for its health benefits, may not be as beneficial as believed; research led by Philip M. Tierno, PhD, clinical professor, Department of Pathology, found that lemon wedges in restaurants can be contaminated with harmful microorganisms, including E. coli, due to inadequate hygiene practices, though lemon water may be helpful for reducing rheumatoid arthritis symptoms when consumed alongside regular medication.